Share capital increase

On 29 October 2010 the general assembly in DiaGenic ASA resolved a private placement of 140 million new shares and a subsequent offering of up to 60 million new shares, both at a subscription price of NOK 0.50 per share. The share capital increase from the private placement of 140 million new shares has now been registered with the Norwegian Register of Business Enterprises. Following the registration, DiaGenic’s share capital is NOK 10,511,826, divided into 210,236,520 shares, each with a nominal value of NOK 0.05. The Articles of Association of the Company have been revised accordingly. Please find attached updated company certificate.

The new shares in DiaGenic ASA are from now on tradable on Oslo Børs.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act).


Erik Christensen, CEO

Telephone: 47 95939918


About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit

About Us

NEL ASA is a leading global supplier of hydrogen technology for industrial / energy purposes, and has made over 500 deliveries in more than 50 countries. The company's main products are hydrogen production plants based on water electrolysis, complete hydrogen stations for transport and renewable energy storage solutions. The company has its roots from the hydrogen activities of Norsk Hydro, which dates back to 1927. The company also has a number of patents related to tests for early detection and diagnosis of diseases.


Documents & Links